December 14, 2021/FSDH
Please be informed that the Fidson Healthcare Plc (“Fidson” or the “Company”) Series 2 Commercial Paper (“CP”) of up to ₦2.0 Billion under its ₦10 billion CP Programme (the “Programme”) is scheduled to closes now.
Fidson is one of the leading pharmaceutical manufacturing companies in Nigeria. The Company is engaged in the manufacturing, marketing and sales of pharmaceutical and healthcare products in Nigeria and West Africa. Fidson currently has over 250 duly registered pharmaceutical brands, across different therapeutic areas, in the Nigerian market. The Company recorded ₦21.8 Billion in year-to-date Sales in its September 2021 financial statements and expects a 3-year CAGR of about 21.4% against the industry average of 5.4%, by the end of the financial year.
Fidson has previously accessed funding through the Capital markets, having issued a ₦4.5 Billion 270-day Commercial Paper in March 2021, a ₦2.3 Billion Rights Issue in July 2019 and a ₦2.0 Billion five-year Secured Fixed Rate Corporate Bond in November 2014.
Please find below a summary of the terms of the offer:
For more information on the offer, kindly access the following documents here:
- Executed Programme Memorandum
- Series II Pricing Supplement
- GCR Credit Rating Announcement
- DataPro Credit Rating Report
- PENCOM Compliance Certificate
- Series II Commitment Form
- Full Year 2020 and Interim 2021 Financial Statements
